Public health interventions that tackle dementia risk factors could yield as much as £4bn in savings in England by reducing dementia rates and helping people to live longer and healthier.
A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections.
Do-it-yourself human papillomavirus tests could enable more than a million more women in England to participate in cervical screening over the next three years, according to a UCL-sponsored trial.
Over 150 people visited a highly successful health and research engagement event in Camden which engaged the local community in healthcare innovation, research, and how to stay healthy.
A UCLH patient is the first person in the UK to receive a new investigational drug being tested for a disorder caused by genetic mutations, called classic congenital adrenal hyperplasia.
UCLH has recruited the first UK participant to a trial of a new immunotherapy drug for patients with advanced solid cancers who no longer respond to existing treatments.
An international clinical trial testing a novel cancer immunotherapy which may prevent skin cancer from recurring has recruited its first patients at UCLH.
UCLH’s trial of the world’s first ‘gene silencing’ drug for Alzheimer’s disease has progressed into a larger and later stage trial, after promising early results.
A world-class research team at UCLH and UCL has been awarded £3.76m to carry out a countrywide trial to identify accurate and quick blood tests that can diagnose dementia.
The UCLH BRC and CRF have published an Equality, Diversity and Inclusion (EDI) strategy to ensure equitable opportunity for all in research, regardless of background.
A new study supported by the NIHR BRC at UCLH has demonstrated the potential of an AI tool to predict the health trajectory of patients by forecasting future disorders, symptoms, medications and procedures.
